Table. Clinical characteristics and results of testing for 3 patients infected with Elizabethkingia anophelis, Hong Kong, 2012*.
| Characteristics | Patient 1 | Patient 2† | Patient 3 |
|---|---|---|---|
| Patient age/sex | 21 d/M | 33y/F | 0 d/F |
| Signs/symptoms |
Fever |
Fever, PPROM |
Apnea at birth |
| Blood test results | |||
| Total leukocytes, × 109 cells/L | 16.0 (5.0–19.5) | 15.2 (3.7–9.3) | 5.1 (10.0–27.0) |
| Neutrophils, × 109 cells/L | 6.8 (2.0–9.5) | 12.5 (1.8–6.2) | 1.2 (5.0–17.0) |
| Lymphocytes, × 109 cells/L | 6.8 (2.5–11.0) | 1.7 (1.0–3.2) | 3.4 (3.0–10.0) |
| Monocytes, × 109 cells/L | 2.3 (0.2–1.2) | 0.8 (0.2–0.7) | 0 (0.5–2.0) |
| Hemoglobin, g/dL | 14.0 (11.0–19.0) | 10.7 (11.5–15.4) | 16.1 (13.5–19.5) |
| Platelets, × 109/L | 180 (180–460) | 241 (160–420) | 186 (100–300) |
| C-reactive protein, mg/L |
109 (<8.0) |
108 (<5.0) |
70.6 (<8.0) |
| CSF test results | |||
| Total leukocytes, × 106 cells/L | 1,445 | NA | 5,850 |
| Polymorphs, % | 67 | NA | 1 |
| Lymphocytes, % | 33 | NA | 99 |
| Protein, g/L | 1.33 (0.15–0.45) | NA | 2.69 (0.15–0.45) |
| Glucose, mmol/L | 2.2 (2.8–4.4) | NA | 1.5 (2.8–4.4) |
| CSF/serum glucose, % |
38 |
NA |
24 |
| Positive culture sites for E. anophelis |
Blood, CSF |
Placental swab, uterine swab |
Blood, CSF |
| Phenotypic characteristics of isolates | |||
| Colony pigment | Pale yellow | None | None |
| Citrate utilization |
Negative |
Delayed positive |
Delayed positive |
| Antimicrobial drug susceptibilities of isolates | |||
| Ampicillin | Resistant | Resistant | Resistant |
| Pipercillin | Susceptible | Susceptible | Susceptible |
| Cefoperazone/sulbactam | Susceptible | Susceptible | Susceptible |
| Cefotaxime | Intermediate | Resistant | Resistant |
| Ceftazidime | Resistant | Resistant | Resistant |
| Imipenem | Resistant | Resistant | Resistant |
| Amikacin | Resistant | Resistant | Resistant |
| Gentamicin | Resistant | Resistant | Resistant |
| Kanamycin | Resistant | Resistant | Resistant |
| Streptomycin | Resistant | Resistant | Resistant |
| Tobramycin | Resistant | Resistant | Resistant |
| Ciprofloxacin | Susceptible | Susceptible | Susceptible |
| Moxifloxacin | Susceptible | Susceptible | Susceptible |
| Tetracycline | Resistant | Resistant | Resistant |
| Trimethoprim/sulfamethoxazole | Susceptible | Susceptible | Susceptible |
| Rifampin | Susceptible | Susceptible | Susceptible |
| Chloramphenicol |
Resistant |
Resistant |
Resistant |
| Vancomycin MIC, μg/mL |
16 |
4 |
4 |
| Antimicrobial drug regimen |
Ampicillin + cefotaxime; vancomycin + piperacillin + rifampin |
Penicillin G; cefuroxime + metronidazole; ciprofloxacin |
Ampicillin + cefotaxime; vancomycin + pipercillin/tazobactam + rifampin |
| Complications | None | None | Respiratory distress, intraventricular hemorrhage |
*Reference ranges are shown in parentheses. PPROM, prolonged premature rupture of membranes; CSF, cerebrospinal fluid. †Mother of patient 3.